참고문헌
- Sabiston DC, Townsend CM. Sabiston textbook of surgery: the biological basis of modern surgical practice. 19th ed. Philadelphia: Elsevier Saunders, 2012.
- Hong S, Won YJ, Lee JJ, Jung KW, Kong HJ, Im JS, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat 2021;53:301-315.
- Bakaeen FG, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg 2000;135:635-641; discussion 641-642.
- Kelsey CR, Nelson JW, Willett CG, Chino JP, Clough RW, Bendell JC, et al. Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;69:1436-1441.
- Onkendi EO, Boostrom SY, Sarr MG, Farnell MB, Nagorney DM, Donohue JH, et al. Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy. J Gastrointest Surg 2012;16:320-324.
- Ji X, Bu ZD, Yan Y, Li ZY, Wu AW, Zhang LH, et al. The 8th edition of the American Joint Committee on Cancer tumor-node-metastasis staging system for gastric cancer is superior to the 7th edition: results from a Chinese mono-institutional study of 1663 patients. Gastric Cancer 2018;21:643-652.
- Dave A, Wiseman JT, Cloyd JM. Duodenal adenocarcinoma: neoadjuvant and adjuvant therapy strategies. Expert Opin Orphan Drugs 2019;7:463-472.
- Ryder NM, Ko CY, Hines OJ, Gloor B, Reber HA. Primary duodenal adenocarcinoma: a 40-year experience. Arch Surg 2000;135:1070-1074; discussion 1074-1075.
- Dave A, Wiseman JT, Cloyd JM. Duodenal adenocarcinoma: more questions than answers. Laparosc Surg 2018;2:5.
- Cloyd JM, George E, Visser BC. Duodenal adenocarcinoma: advances in diagnosis and surgical management. World J Gastrointest Surg 2016;8:212-221.
- NCCN. Clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 1.2022 [Internet]. Plymouth Meeting: NCCN 2022 [cited 2022 June 8]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
- Velandia C, Morales RD, Coello C, Mendoza AG, Perez G, Aguero E. Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma. Ecancermedicalscience 2018;12:816.
- Zhang GY, Mao J, Zhao B, Long B, Zhan H, Zhang JQ, et al. Duodenal bulb adenocarcinoma benefitted from neoadjuvant chemotherapy: a case report. Chemotherapy 2017;62:290-294.
- Kaslow SR, Prendergast K, Vitiello GA, Hani L, Berman RS, Lee AY, et al. Systemic therapy for duodenal adenocarcinoma: an analysis of the National Cancer Database (NCDB). Surgery 2022;172:358-364.
- Van Dam JL, Janssen QP, Besselink MG, Homs MYV, van Santvoort HC, van Tienhoven G, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer 2022;160:140-149.
- Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol 2022;40:1220-1230.
- Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol 2019;5:1020-1027.